Hormone Replacement Therapy in Healthy Females and Gynecologic Cancer Survivors

Setareh Akhavan1,

1 Gynecologist Oncologist, Associate Professor, Department of Gynecology Oncology, Valiasr Hospital, Tehran University of Medical Sciences, Tehran, IR Iran

Keywords: Hormone Replacement Therapy, Menopause, Gynecologic Cancer

Hormone replacement therapy (menopausal hormone therapy, MHT) is safe for healthy and symptomatic females who are within 10 years of menopause or younger than 60 and do not have contraindications to MHT such as a history of breast cancer, coronary heart disease, a previous venous thromboembolic event or stroke, or active liver diseases (1).

- MHT should be used in females with a uterus as combination of estrogen-progesterin and unopposed estrogen is recommended in post-hysterectomy. For females with vaginal atrophy symptoms only, vaginal estrogen may be recommended (2).

- MHT is currently not recommended to prevent chronic diseases such as cardiovascular or bone diseases (3).

- No increase in either coronary heart disease (CHD) or breast cancer risk was observed in unopposed estrogen use (4).

- Combined hormone therapy increases CHD events, stroke, venous thromboembolism (VTE) and breast cancer, while it decreases fracture and colorectal cancer risk (5).

- The absolute risk of complications for healthy and postmenopausal females taking MHT for five years is very low (3).

- In gynecologic cancer, all treatment modalities (surgery, chemotherapy or radiation) cause ovarian failure, hypoestrogenism and menopausal symptoms.

- MHT is recommended for a short course only for breast cancer gene (BRCA) mutation carriers undergone risk-reducing hysterectomy and salpingo-oophorectomy (TAH & BSO) for a short course. Only estrogen based at small possible dose recommended. At present there is no evidence to show that HRT is safe in type II endometrial cancer.

- MHT may be recommended as a short course for epithelial ovarian cancer survivors with symptoms. In survivors that their tumors express estrogen-progesterone, extreme caution is necessary.

- MHT appears to be safe in cervical cancer survivors (6).

References


